Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
· financialpost.com
TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), has reported its financial a…
Stay up to date on the best insured and uninsured mortgage rates in Canada. Read now >>
Stay up to date on the best insured and uninsured mortgage rates in Can...